Hannagan Keri相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events

类风湿性关节炎三联疗法与依那西普的比较：感染和胃肠道不良事件的差异

期刊:Rheumatology

影响因子:4.4

doi:10.1093/rheumatology/kew412

Quach, Lien T; Chang, Bei-Hung; Brophy, Mary T; Soe Thwin, Soe; Hannagan, Keri; O'Dell, James R

发表日期：2017

文献求助收藏

Design and conduct of a provider survey to determine a clinically persuasive effect size in planning VA Cooperative Study #590 (Li+)

设计和实施一项提供者调查，以确定在规划 VA 合作研究 #590 (Li+) 中具有临床说服力的效果量

期刊:Contemporary Clinical Trials Communications

影响因子:1.4

doi:10.1016/j.conctc.2016.08.004

Harrington, Kelly M; Liang, Matthew H; Hannagan, Keri; Thwin, Soe Soe; Ferguson, Ryan E; Morgenstern, Natalie; Flores, Erick; Katz, Ira R

发表日期：2016

文献求助收藏

Making smart investment decisions in clinical research

在临床研究中做出明智的投资决策

doi:10.1186/s13063-015-1123-1

Bansback, Nick; Keystone, Edward; O'Dell, James; Phibbs, Ciaran S; Hannagan, Keri; Brophy, Mary; Anis, Aslam

发表日期：2015

文献求助收藏

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.

晚期乳腺癌的联合抗血管生成疗法：一项 VEGFR 抑制剂凡德他尼和节拍化疗的 1 期试验，并结合血小板蛋白质组学分析

期刊:Breast Cancer Research and Treatment

doi:10.1007/s10549-012-2256-5

Mayer Erica L, Isakoff Steven J, Klement Giannoula, Downing Sean R, Chen Wendy Y, Hannagan Keri, Gelman Rebecca, Winer Eric P, Burstein Harold J

发表日期：2012

文献求助收藏